For years I was (and still I am) confident, that Alzheiemr's is such a corrupted research field, that one can take an academic leave for three, five, or even ten years, and then come back exactly to the date he or she left. Those bastards and mafia-like strucrure of academic science and hidden big pharmaceutical bucks behind them leaves no space for an open minded innovative ideas. Don't ask how it is possible, it is the way Alzheimer's research exists for two decades.
So, I decided to remove digital dust out of my advocacy, scientific and lay language writings and make it public here, so, you, Dear Reader, has original content from the author, directly and with no "dealers", such as poor and often corrupted academic journals.
...It was no surprise that three days later Eli Lilly announced the halt of Alheimer's therapy trial, as patients worsen on a chemical called secretase inhibitor, which is an anti-amyloid beta therapy based on ill-fated and poor-minded (yet commercially, but not public succesful) amyloid hypothesis (read dogma) of Alzheimer's disease.
Today, by the end of the day August 19, I decided to start another theme web site, devoted exclusively to reprinting Alzheimer's news and press releases from different sources. I thus would like to separate my original content from content by others. I will still announce interesting news at major AlzClub.org web site by providing brief summary and linking to a full text at the news site and the article source. All other web sites, including Alzheimer's History, Alzheimer's Amyloid beta courses for Public and Professionals, Alzheimer's Code and emerging projects will be syndicating the content of each other, so, every new material will be visible, and just click away no matter at which particular site you are at the moment.
Surely, all the projects are non-profit, public and ad supported: while I do not expect to make revenue, it will be nice to have an advertisement support coveingr my internet publishing and associated expenses.
Remaining independent and truly yours,
Alexei Koudinov, MD, PhD, DrSci
neuroscientist, Alzheimer's researcher
a man of 44 who loves this world
P.S. First annotated by me news item to follow in just another 10 minutes or so, with Press release of Alzheimer's Association of Chicago, IL on Eli Lilly Alzheimer's clinical trial termination, stay connected, and yes, follow me on twitter
0 comment(s):
Post a Comment